Breaking News

Financial Report: Amgen

February 1, 2016

Product sales increased 3% in the quarter

Amgen
 
4Q Revenues:
$5.5 billion (+4%)

4Q Earnings: $1.8 billion (+39%)

FY Revenues: $6.9 billion (+35%)

FY Earnings: $21.7 billion (+8%)

Comments: Product sales increased 3% in the quarter, with growth driven by Enbrel (+8% to $1.4 billion), Sensipar(+21% to $384 million), Prolia (+21% to $380 million), Kyprolis (+63% to $148 million), and XGEVA (+10% to $356 million). Neulasta sales were down 2% to $1.2 billion, Neupogen sales were down 4% to $263 million, and Epogen sales were down 37% to $342 million, due to competition.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks